News Medical on MSN3d
FDA approves Romvimza for tenosynovial giant cell tumor (TGCT)
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...
Medindia3d
FDA Approves Vimseltinib to Treat Tenosynovial Giant Cell Tumor
Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, ...
Medscape9d
FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumors
The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult ...
Targeted Oncology9d
Vimseltinib Gains FDA Approval in Tenosynovial Giant Cell Tumor
Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the ...
Monthly Prescribing Reference5d
Romvimza Approved for Symptomatic Tenosynovial Giant Cell Tumor
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
Targeted Oncology21h
The Targeted Pulse: Hot Off-The-Press Approvals and What to View from ASCO GU 2025
FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
Mena FN20d
Tenosynovial Giant Cell Tumors Market To Grow At 19.1% CAGR By 2034 Says Delveinsight
(MENAFN- EIN Presswire) Innovators like Abbisko Therapeutics, Merck, and AmMax are revolutionizing Tenosynovial Giant Cell Tumor care, pushing boundaries to elevate patient well-being. LAS VEGAS ...